Who is sponsoring NCT02303899?

NCT02303899 is sponsored by Istituto Clinico Humanitas.

What condition does NCT02303899 study?

NCT02303899 studies Mesothelioma, Malignant.

What drugs are being tested in NCT02303899?

Interventions: Gemcitabine, Imatinib mesylate.

What is the status of NCT02303899?

NCT02303899 is currently COMPLETED.

Last reviewed 2021-01-20 · How we verify

A Phase II Study of the Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Malignant Pleural Mesothelioma

NCT02303899 Phase 2 COMPLETED

This is a phase II, monocentric study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with MPM expressing PDGFR-beta and/or C-kit by Immunohistochemistry (IHC). Treatment will be done until disease progression, or patient refusal or withdrawal of patient consent, or unacceptable toxicity

Details

Lead sponsor	Istituto Clinico Humanitas
Phase	Phase 2
Status	COMPLETED
Enrolment	22
Start date	2014-11
Completion	2017-12

Conditions

Mesothelioma, Malignant

Interventions

Gemcitabine
Imatinib mesylate

Primary outcomes

anti-tumor activity of Imatinib mesylate in combination with Gemcitabine — 12 weeks
assess the anti-tumor activity of Imatinib mesylate in combination with Gemcitabine, in terms of 3-months progression-free survival (PFS) rate

Countries

Italy